Copyright ©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Figure 2
Figure 2 Possible sequential therapies of molecular targeted agents for hepatocellular carcinoma in the real-world practice[53]. There are solid evidence for use of regorafenib, ramucirumab, cabozantinib after sorafenib as confirmed by RESORCE, REACH-2 and CERESTIAL trials. However, lenvatinib has been proven to be effective after sorafenib or regorafenib in the real world practice as a second-line or third-line agent. Effectiveness of second-line agents after lenvatinib failure should be explored in the real-world practice setting. AFP: Alphafeto protein.